In a real-world clinical setting at an academic health system, lecanemab-treated patients generally experienced a cognitive and functional decline, as expected from the phase 3 trial. Infusion-related reaction rates were higher than observed in the phase 3 trial. ARIA-E rates were generally similar to what was reported in the clinical trial, but the ARIA-H rates were generally higher.

INTRODUCTION

Lecanemab is an anti-amyloid therapy for early symptomatic Alzheimer’s disease, with side effect of Infusion-related reactions (IRR) and amyloid-related imaging abnormalities (ARIA).1

1van Dyck et al., NEJM, 2023

METHODS